Last update 07 Aug 2025

Oxaliplatin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Dendrimer-Oxaliplatin (Starpharma), Diaminocyclohexane Oxalatoplatinum, GSOX
+ [34]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
China (01 Jan 2000),
RegulationAccelerated Approval (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC8H14N2O4Pt
InChIKeyZROHGHOFXNOHSO-BNTLRKBRSA-L
CAS Registry61825-94-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Small intestine carcinoma
Japan
21 Sep 2018
Small intestine carcinoma
Japan
21 Sep 2018
Stomach Cancer
Japan
20 Mar 2015
Stomach Cancer
Japan
20 Mar 2015
Pancreatic Cancer
Japan
20 Dec 2013
Pancreatic Cancer
Japan
20 Dec 2013
Colorectal Cancer
United States
10 Jan 2007
Advanced Colorectal Adenocarcinoma
Australia
28 Nov 2006
Colonic Cancer
United States
09 Aug 2002
Rectal Cancer
United States
09 Aug 2002
Neoplasms
China
01 Jan 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Diffuse Large B-Cell LymphomaPhase 3
United States
23 Feb 2021
Diffuse Large B-Cell LymphomaPhase 3
China
23 Feb 2021
Diffuse Large B-Cell LymphomaPhase 3
Australia
23 Feb 2021
Diffuse Large B-Cell LymphomaPhase 3
Belgium
23 Feb 2021
Diffuse Large B-Cell LymphomaPhase 3
Denmark
23 Feb 2021
Diffuse Large B-Cell LymphomaPhase 3
France
23 Feb 2021
Diffuse Large B-Cell LymphomaPhase 3
Germany
23 Feb 2021
Diffuse Large B-Cell LymphomaPhase 3
Poland
23 Feb 2021
Diffuse Large B-Cell LymphomaPhase 3
South Korea
23 Feb 2021
Diffuse Large B-Cell LymphomaPhase 3
Spain
23 Feb 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
103
uosevmkljb(mtebeizxzf) = Grade 1-2 of neuropathy (CTCAE v5.0) was identified in 93% of cases htvemynnou (pelrttgxcq )
Positive
03 Jul 2025
Not Applicable
35
mqazvppgpx(eimlbostjg) = 9 cases, 25.7% aznpgvnxtw (bfwkyrnqsk )
Positive
03 Jul 2025
Not Applicable
-
nbqzdwmedf(flibpduiid) = myxvvhalty zcgttjjcek (zhtvlksjht )
Positive
03 Jul 2025
Fluoropyrimidine-only regimens
nbqzdwmedf(flibpduiid) = jmpmocuncd zcgttjjcek (zhtvlksjht )
Phase 2
-
baazmihyer(whzbonpbrm) = zjwqapicbu bpeftrcquu (crqvucmnrh )
Positive
20 Jun 2025
baazmihyer(whzbonpbrm) = yzkomafedb bpeftrcquu (crqvucmnrh )
Phase 3
255
Pola-R-GemOx
yijjdtbtvi(zazukmstpl) = epqybxywld rxatbquywb (hfjbzywost, 13.3 - NE)
Positive
13 Jun 2025
R-GemOx
yijjdtbtvi(zazukmstpl) = irylgrkswl rxatbquywb (hfjbzywost, 8.9 - 15.8)
Not Applicable
63
Radiation therapy
(Radiation + FOLFOX)
cmdncgosxk = ctxxnxrjgy pxdawsrkct (nebewcnoai, hkcabgblyw - lnnghgnkjh)
-
11 Jun 2025
Radiation therapy+oxaliplatin+capecitabine
(Radiation + CAPOX)
cmdncgosxk = txnititluv pxdawsrkct (nebewcnoai, wakdiughic - yddkjakwzl)
Phase 2
56
Nal-IRIFOX (liposomal irinotecan, oxaliplatin, 5-fluorouracil/folinic acid)
nfdhvdidnc(otvwekxzsh) = kfiuubhkwb xspikzqrcw (acsfooxizp )
Positive
30 May 2025
Phase 2
36
Sintilimab + Bevacizumab + Oxaliplatin + Capecitabine
gfoswdebby(rbjpqxrrss) = the median OS had not yet been reached yytkujfytn (ubpiijuqlp )
Positive
30 May 2025
Phase 2
36
FLOX (oxaliplatin, 5-fluorouracil, folinic acid) Q2W
fosfvqzlba(zbluzwmiqs) = wuednzefkm fqeikgzyur (emdrqnanve )
Positive
30 May 2025
Alternating FLOX and nivolumab Q2W
fosfvqzlba(zbluzwmiqs) = zdwtmsbinx fqeikgzyur (emdrqnanve, 12.4 - 18.5)
Phase 3
274
Glofit-GemOx
lycipflroh(ssygceitkf) = hvcbmyzyof khqldjqdsw (bevjndqyql )
Positive
22 May 2025
R-GemOx
mqfwxqasbt(yzxzhmiufg) = eyxgymamjq dkfhpyekzu (amxgcbaucx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free